SCHEMBL3138743

SCHEMBL3138743

CCC1CCC(c2ccc(OCC3Cn4ccc(=O)nc4O3)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 10/20 0.65
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK1 P28482 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.33
ACACB O00763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133816 0.89 GRM2 (0.68) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL1515985 0.88 GRM2 (0.65) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL1515988 0.88 GRM2 (0.65) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3138329 0.88 GRM2 (0.67) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3138336 0.88 GRM2 (0.67) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3138731 0.88 GRM2 (0.67) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3138681 0.87 GRM2 (0.70) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3134494 0.87 GRM2 (0.66) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3138739 0.86 GRM2 (0.65) GRM2L3MBTL1POLBKMT2ASMN1; SMN2
SCHEMBL3138692 0.85 GRM2 (0.63) GRM2L3MBTL1POLBKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C GRM2 1/4885L3MBTL1 3899/4885POLB 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.